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Purpose: To identify genes whose expressions in primary human trabecular meshwork (TM) cell cultures are affected by
the transcription factor pituitary homeobox 2 (PITX2) and to identify genes that may have roles in glaucoma. Known
glaucoma causing genes account for disease in a small fraction of patients, and we aimed at identification of other genes
that may have subtle and accumulative effects not easily identifiable by a genetic approach.
Methods: Expression profiles derived using microarrays were compared between TM control cells and cells treated with
PITX2 siRNAs using three protocols so as to minimize false positive and negative results. The first protocol was based
on the commonly used B statistic. The second and third protocols were based on fold change in expression. The second
protocol used a threshold of at least 2 fold change in expression, whereas the third protocol used ranking in fold change
without setting a threshold. The likelihood of a selected gene being a true positive was considered to correlate with the
number of protocols by which it was selected. By considering all genes that were selected by at least one protocol, the
likelihood of false negatives was expected to decrease. Effects on a subset of selected genes were verified by real time
PCR, western blots, and immunocytochemistry. Effects on ALDH1A1, were further pursued because its protein product,
aldehyde dehydrogenase 1 family, member A1, has roles in oxidative stress and because oxidative stress is known to be
relevant to the etiology of glaucoma.
Results: The expression level of 41 genes was assessed by to be possibly affected by PITX2 knockdown. Twenty one
genes were down-regulated and twenty were upregulated. The expression of five genes was assessed to be altered by all
three analysis protocols. The five genes were DIRAS3 (DIRAS family, GTP-binding RAS-like 3), CXCL6 (chemokine
(C-X-C motif) ligand 6), SAMD5 (sterile alpha motif domain containing 5), CBFB (core-binding factor, beta subunit),
and MEIS2 (meis homeobox 2). Real time PCR experiments verified results on a subset of genes tested. Notably, the
results were also confirmed in two independent TMs. Effects on CXCL6 and ALDH1A1 were also confirmed by western
blots, and effects on ALDH1A1 were further shown by immunocytochemistry. Data consistent with PITX2 involvement
in ALDH1A1 mediated response to oxidative stress were presented.
Conclusions: Bioinformatics tools revealed that the genes identified affect functions and pathways relevant to glaucoma.
Involvement of PITX2 in expression of some of the genes and in some of the pathways is being reported here for the first
time. As many of the genes identified have not been studied vis-à-vis glaucoma, we feel they introduce new candidates
for understanding this devastating disease.
Pituitary  homeobox  2  (PITX2)  is  a  homeobox
transcription  factor  (TF)  related  to  the  paired  class  of
homeodomain  proteins  [1].  It  affects  the  development  of
various  ocular  tissues.  During  murine  embryonic
development,  PITX2  is  expressed  in  neural  crest  and
mesoderm  precursors,  both  of  which  contribute  to  the
periocular mesenchyme [2]. Mice carrying targeted deletions
in  PITX2  exhibit  eye  development  defects  that  include
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agenesis  of  the  corneal  epithelium  and  stroma,  loss  of
extraocular  muscles,  and  abnormalities  of  the  optic  nerve
[3-5]. Finally, mutations in PITX2 are cause of Axenfeld-
Rieger syndrome (ARS) in a subset of patients [6,7]. ARS is
characterized by defects in the anterior segment of the eye and
systemic malformations [6,7]. Notably, approximately 50%
of ARS patients develop glaucoma, usually in adolescence or
early adulthood [8]. ARS patients harboring PITX2 mutations
are among those at risk of developing glaucoma [8].
The fact that mutations in PITX2 can cause the ARS
phenotype and that the mutations may culminate in a non-
congenital form of glaucoma may be signatures of PITX2
functions in the mature TM [9]. Here, we report the effects of
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Tehran, Iran; 
Tehran, Tehran, Iran; siRNA knockdown of PITX2 on global gene expression in
primary  human  TM  cell  cultures  using  high  density
microarrays.  Pathways  and  functions  implicated  for  the
affected  genes  were  derived  using  bioinformatics  tools.
CXCL6 (chemokine (C-X-C motif) ligand 6) which has roles
in immune response and ALDH1A1 (aldehyde dehydrogenase
1 family, member A1) which has roles in oxidative stress were
among the affected genes. The effects of the knockdown on
ALDH1A1 were further pursued [10,11].
METHODS
This research was performed in accordance with the Helsinki
Declaration  and  with  approval  of  the  ethics  board  of  the
University of Tehran. Eye globes were obtained from the
Central Eye Bank of Iran.
Preparation  of  primary  TM  cultures:  Four  primary
cultures were developed from donors without history of eye
disease aged 25 (male; TM1), 30 (male; TM2), 65 (male;
TM4), and 60 (female; TM5) years old at time of death [12].
Cells  were  maintained  as  previously  described  [12].  The
nature of the cells was confirmed by demonstrating increased
expression  of  myocilin  mRNA  and  protein  upon
dexamethasone treatment (data not shown) [12].
siRNA treatment and RNA extraction: Fourth to sixth
passage cells were used in all experiments. Each of the four
TM  cultures  was  exposed  to  three  siRNA  treatments  in
duplicate  wells.  Lipofectamine  RNAiMAX  (Invitrogen,
Carlsbad, CA) was used for reverse transfection according to
the manufacturer’s instructions. We had previously shown
that this treatment has no detectable effect on cell growth (data
not shown). Approximately 8×104 cells were added to wells
containing siRNA to achieve a final siRNA concentration of
75  nM.  These  siRNA  duplices  (Dharmacon  Research,
Lafayette, CO) were used: PITX2 siRNA-1 (J-017315–05),
PITX2  siRNA-2  (J-017315–06),  and  scrambled  siRNA-1
(D-001810–01–20). All TM cultures had two independent
treatments with scrambled siRNA (i.e., two treatments, two
wells for each) so as to enable testing of technical replication
of the array expression assessments.
Forty eight hours after exposure to siRNAs, cells were
harvested and cells of duplicate wells were combined and
placed in RNXTM-plus (Cinnagen, Tehran, Iran). Total RNA
was  isolated  according  to  the  manufacturer’s  instructions.
RNA quality was assessed using density ratio of 28S to 18S
rRNA bands. Half of the RNA was set aside for microarray
experiments and the other half was used for real time PCR.
Assessment of knockdown by siRNAs: Candidate control
genes  for  assessment  of  effects  of  PITX2  siRNAs  were
ACTB  (actin,  beta),  β2M  (beta-2  microglobulin),  GAPDH
(glyceraldehyde-3-phosphate  dehydrogenase),  and  HPRT1
(hypoxanthine phosphoribosyltransferase 1). cDNA synthesis
was done by standard procedures and real time PCR was
performed on a Corbett 65H0 machine (Corbett Research,
Sidney, Australia) using the QuantiFast SYBR Green PCR Kit
(QIAGEN, Germantown, MD). After selection of appropriate
control  gene  using  GNorm  program  [13],  PITX2  siRNA
knockdown effects on PITX2 were determined by real time
PCR.  The  real  time  PCR  primers  were  obtained  from
QIAGEN.
Microarray  experiments  and  data  analysis:  Array
experiments were performed only on TM1 and TM2 cultures
using HumanRef-8 V2 Illumina Genome-Wide Expression
BeadChips  according  to  the  manufacturer’s  instructions
(Illumina, San Diego, CA). Arrays were scanned with the
Illumina BeadArray reader and images were analyzed using
Beadstudio  VI  software.  The  Beadstudio  data  were
normalized using a quantile based algorithm available in the
Beadarray software [14]. Values for all genes were compared
between  the  two  replicate  control  samples  of  TM1  and
between the two replicate control samples of TM2. Similarly,
effect of PITX2 siRNA treatments on three housekeeping
genes ACTB, β2M, and GAPDH on the different arrays were
determined. Subsequently, genes the expressions of which
were affected by siRNA treatments were assessed based on
three protocols as described below.
First, the Limma package was used [15]. For each of the
four assessments (two siRNAs, two TMs), genes were ordered
based on the value of their associated B statistic. Genes were
then selected on conditions that they had a B statistic value
≥2 in at least two of the four assessments, that both siRNAs
were represented in these assessments, and that the direction
of change in expression was the same in the assessments.
In the second protocol, expression in presence of each of
two siRNAs was compared separately to each of two controls
for each TM, producing eight comparisons for the two TMs.
Genes were selected on conditions that they showed ≥2 fold
change in the same direction in at least four of the eight
comparisons and that each siRNA was represented at least
once among the selected comparisons.
In the third protocol, essentially the 40 top ranking genes
affected  by  siRNAs  of  PITX2  based  on  fold  change  in
expression  were  selected.  Initially,  fold  changes  in  the
presence of siRNA1 in each TM were assessed by comparison
to average of controls for the respective TM, and forty top
ranking genes in each TM were identified (Group A genes:
siRNA-1  top  40  TM1  list,  siRNA-1  top  40  TM2  list).
Subsequently, genes affected were sorted by adding rank of
genes affected in the two TMs, and selecting the top 40 genes
(Group A genes: siRNA-1 top 40 TM1/2 list). This process
was repeated for siRNA-2 (Group B genes: siRNA-2 top 40
TM1 list, siRNA-2 top 40 TM2 list, siRNA-2 top 40 TM1/2
list). Finally, the rankings of genes affected by both siRNAs
in each TM were added, and then the rankings of both siRNAs
in both TMs were added (Group C genes: siRNA-1/2 top 40
TM1 list, siRNA-1/2 top 40 TM2 list, siRNA-1/2 top 40
TM1/2 list). In this protocol, genes were ultimately selected
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genes. A computer program written to perform this selection
task is available at Joint-rank.
Real time PCR: Real time PCR was performed on a subset
of microarray based selected genes on the two TMs that had
been used for microarray analysis and also on TM4 and TM5.
cDNA  synthesis  and  real  time  PCR  were  performed  as
described  above  using  QIAGEN  primers  for  ACTB,
ALDH1A1, CXCL6, DIRAS3 (DIRAS family, GTP-binding
RAS-like  3),  DKK1  (Dickkopf-1),  KCNJ2  (potassium
inwardly-rectifying  channel,  subfamily  J,  member  2),
MEIS2 (meis homeobox 2), PITX2, and SAMD5 (sterile alpha
motif domain containing 5). At least four replicate PCRs for
each gene in each TM were performed. Detailed information
on all primers is provided in Table 1. ACTB was used as
control gene in the real time PCR experiments except where
indicated otherwise. Fold change in expression of selected
genes were obtained using software provided by the Corbett
instrument, used for the real time PCR experiments..
Western blot analysis: TM cultured cells were harvested
and lysed in Lameli lysis buffer. Protein (60–100 µg) was
electrophoresed  on  10%–15%  denaturing  polyacrylamide
gels  and  the  resolved  proteins  were  transferred  onto
nitrocellulose membranes. The ECL Advance Luminol based
chemiluminescence detection kit was used for detection of
specific proteins after reaction with appropriate antibodies
according to the manufacturer’s instructions (GE Healthcare,
Salt  Lake  City,  UT).  Specific  antibodies  used  were  goat
polyclonal antibodies (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA) against human myocilin (C-15), Lamin B (C-20)
and rabbit polyclonal antibodies (Abcam, Cambridge, MA)
against ALDH1A1 (ab51028) and CXCL6 (ab9923). Lamin
served  as  control  protein.  Secondary  antibodies  were
horseradish peroxidase conjugated anti-goat (SC-2768; Santa
Cruz Biotechnology) and anti-rabbit (Sigma-Aldrich, Poole,
UK) antibodies. Western blot analysis for each protein was
performed twice.
Immunofluorescence  analysis  on  cultured  cells  and
histological sections: TM1 cells grown on coverslips in the
presence of scrambled siRNA or PITX2 siRNA-1 were fixed
with an acetone-methanol mix, blocked with BSA, incubated
with  the  anti-ALDH1A1  antibody  described  above,  and
exposed to fluorescent conjugated goat anti-rabbit secondary
antibody (AF8035; Razi BioTech, Tehran, Iran). Nuclei were
counterstained with DAPI (Invitrogen). Cells were visualized
with an Axioplan 2 fluorescence microscope (Carl Zeiss, Jena,
Germany). Additionally, expression of both ALDH1A1 and
CXCL6 were assessed in cryosections of a globe from a three
year old cadaver.
Comparison  of  genes  identified  to  genes  reported  in
previous glaucoma relevant array studies: Fifteen microarray
gene expression studies in which effects of various glaucoma
relevant  conditions  or  treatments  were  studied,  including
effects  of  dexamethsone,  pressure,  TGFβ,  and  gene
knockdown,  have  been  reported  [16-30].  PITX2  affected
genes identified here were compared to genes identified in the
previous studies to identify possible commonalities.
In silico analysis of selected genes: Promoter regions of
selected genes were screened for PITX2 binding sites so as to
identify  genes  whose  transcriptions  are  more  likely  to  be
directly affected by this TF. PITX2 binds the bicoid sequence
element 5ʹ-TAATCC-3ʹ [31,32]. The region between 3,000 bp
upstream and 200 bp downstream of transcription initiation
sites of potential target genes was screened for presence of the
element [33,34]. Finally, genes identified by the microarray
analysis  were  analyzed  to  identify  potentially  relevant
functional  pathways  and  functional  categories  or  gene
ontology terms annotated by Kyoto Encyclopedia of Genes
and Genomes (KEGG) [35] and Gene Ontology (GO) [36]
using  the  Database  for  Annotation,  Visualization,  and
Integrated Discovery (DAVID) bioinformatics tool [37]. A
cutoff p value of 0.05 was used for enriched KEGG pathways
or GO functions.
TABLE 1. PRIMERS USED IN REAL TIME PCR EXPERIMENTS.
Gene* Entrez gene ID QIAGEN Cat. # Target transcript Amplified exons Amplicon length
(bp)
ACTB 60 QT01680476 NM_001101 ** 104
ALDH1A1 216 QT00013286 NM_000689 11, 12 97
B2M 567 QT00088935 NM_004048 1,2 98
CXCL6 6372 QT00211155 NM_002993 2 75
DIRAS3 9077 QT00040558 NM_004675 3,4 60
DKK1 22943 QT00009093 NM_012242 2,3 137
GAPDH 2597 QT01192646 NM_002046 1,2,3 119
KCNJ2 3759 QT00001022 NM_000891 1,2 150
MEIS2 4212 QT00077315 NM_002399 6,7,8 143
PITX2 5308 QT01006033 NM_153426 3,4 104
SAMD5 389432 QT01154223 NM_001030060 1,2 105
*HPRT primers were designed by us. **Data not provided by QIAGEN.
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treatments: H2O2 and LiCl treatments were used, respectively,
as surrogates for analysis of effects of oxidative stress and Wnt
signaling  [38,39].  For  assessment  of  these  agents  on
expression of PITX2 and ALDH1A1, TM1 cells were exposed
to five treatments and each treatment had its own control. The
first treatment was exposure to PITX2 siRNA, and control
treatment was exposure to scrambled siRNA. In the second,
cells were exposed to 600 mM H2O2 for 4 h, and in the third
treatment cells had the same exposure to H2O2 after having
been exposed to PITX2 siRNA-1. The fourth treatment was
exposure to 20 mM LiCl for 12 h. In the fifth treatment,
H2O2 was added to cells that had already been exposed to LiCl
for 12 h, and incubation was continued for an additional 4 h.
After  treatments,  real  time  PCR  was  performed  to  assess
levels of PITX2 and ALDH1A1 expression. β2M was used as
control gene because H2O2 has been reported to affect actin
expression [39]. The effects of the H2O2 and LiCl treatments
on  ALDH1A1  expression  were  also  assessed  by  western
analysis.  Statistical  analysis  was  done  using  Relative
Expression Software Tool (REST) software [40].
RESULTS
GNorm identified ACTB and β2M as genes with best stability
value  (M=0.028).  The  amount  of  knockdown  of  PITX2
mRNA by its siRNAs using ACTB as control in the four TM
cultures (TM1, TM2, TM4, TM5) ranged from 76%–93% and
the average was 84% as assessed by real time PCR (Figure 1).
The  raw  microarray  data  on  TM1  and  TM2  have  been
deposited in the Gene Expression Omnibus (GEO) database,
(accession GSE27275). The levels expression of most genes
in the two independent TM1 culture control samples that had
been treated in identical manner with scrambled siRNA were
very similar and only one gene showed >│2.0│fold change
in  expression  between  the  two  replicates  (GTF21;  2.1×).
Similarly,  only  one  gene  showed  >│2.0│fold  change  in
expression between the two independent scrambled siRNA
treated TM2 cells (TAF5L; 2.1×). These results are indicative
of  acceptable  experimental  replication.  Fold  change  in
expression  of  three  housekeeping  genes  ACTB,  β2M,  and
GAPDH due to PITX2 siRNA treatments was low for the
siRNAs in both TM1 and TM2, averaging 1.01 (Table 2).
Microarray  data  analysis:  Protocols  1,  2,  and  3
identified,  respectively,  26,  14,  and  20  genes  affected  by
PITX2  siRNA  treatments,  and  some  genes  were  common
between genes selected by different protocols. In total 41
different genes were identified, and these will henceforth be
called “PITX2-filtered genes.” Nine genes were identified by
two protocols and five by all three of the protocols. The genes
identified are listed in Table 3. The five genes identified by
all the protocols were DIRAS3, CXCL6, SAMD5, CBFB (core-
binding factor, beta subunit), and MEIS2. Known glaucoma
causing  genes,  CYP1B1  (cytochrome  P450,  family  1,
subfamily  B,  polypeptide  1),  MYOC  (myocilin),  OPTN
(optineurin), and WDR36 (WD repeat domain 36) were not
among  the  genes  affected  by  PITX2  [41].  LTBP2  (latent
transforming growth factor beta binding protein 2), a primary
glaucoma causing gene, was not probed on the arrays [42].
To confirm microarray based assessments, real time PCR
was performed on a subset of genes. Five genes affected by
PITX2  siRNAs,  ALDH1A1,  CXCL6,  DIRAS3,  MEIS2,
SAMD5,  and  two  additional  candidate  genes,  DKK1  and
KCNJ2, were tested. The latter two were not among the genes
identified by the array analysis protocols; they were selected
for assessment by real time PCR based on earlier reports
suggesting PITX2 may affect their expressions [17,43,44].
Effects  of  PITX2  siRNAs  as  assessed  by  real  time  PCR
corroborated the array data of most genes tested in the sense
of the genes being down-regulated or upregulated (Figure 2).
The only exception was MEIS2 in TM2. Notably, the effects
on the genes observed in TM1 and TM2, were also observed
in  TM4  and  TM5  which  originated  from  globes  of  older
individuals. DKK1 and KCNJ2 that had not been selected by
criteria of the array analysis protocols were also shown by real
time PCR to be affected by PITX2 knockdown. Although the
array data on these two genes did not meet the protocols
selection criteria, the array data did in fact indicate some
down-regulation consistent with the real time PCR results
(Figure 2).
CXCL6 and ALDH1A1, were further analyzed by western
blotting,  and  the  results  evidenced  that  PITX2  siRNAs
affected decreased expression of CXCL6 and ALDH1A1 at
the  protein  level  (Figure  3A).  Furthermore,  decreased
expression of ALDH1A1 protein in PITX2 siRNA treated
cells was also shown by immunofluorescence analysis of the
treated cells (Figure  3B-G).  Immunofluorescence on  globe
sections showed expression of both genes in the trabecular
meshwork,  and  additionally  in  the  stroma  and  Descemet
membrane (Figure 3H-S).  Highest  expressions  of  CXCL6
and   ALDH1A1   were   observed,   respectively   in   the  iris
epithelium and corneal epithelium.
Of the 41 PITX2-filtered genes identified by analysis of
array data, 11 were also identified in one or more previously
reported  glaucoma  related  global  gene  expression  studies
(Table 4). Notably, DIRAS3 and CXCL6 that had shown the
two highest fold changes in our experiments (3.9X and 3.3×,
respectively; Table 3) and that had both been selected on the
basis of all three selection protocols, had also been repeatedly
reported  in  other  studies  [17-20].  ADAMTS5  that  was
identified  by  only  one  of  our  selection  protocols  was
previously reported in three studies [17,21,22]. DKK1 and
KCNJ2 which were shown to be affected by PITX2 siRNAs
by real time PCR experiments were each previously reported
in one study [16,22].
In silico analysis of selected genes: The PITX2 binding
element  was  identified  within  regions  surrounding  the
transcription initiation sites of some of the affected genes. Of
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1212the 41 PITX2 filtered genes, 18(43.9%) contained two or more
of  the  binding  sequences  (data  not  shown).  For  example,
DKK1 and MEIS2 had, respectively, four and three binding
sites. Table 5 lists KEGG and GO terms that are enriched
among the 41 PITX2 affected genes.
Oxidative  stress  and  Wnt  signaling:  PITX2  siRNA
decreased PITX2 (−9.1×) and ALDH1A1 (−4.3×) expression
as already described above (Figure 4A). As ALDH1A1 is
known to be involved in the oxidative stress response of the
eye, effect of H2O2 on PITX2 and ALDH1A1 expression was
tested. Under the condition of acute exposure to H2O2 used
here, real time PCR showed that it decreased both PITX2
(−3.2×) and ALDH1A1 (−3.9×) expression (Figure 4A). Effect
of H2O2 on ALDH1A1 expression at the protein level was also
evident  (Figure  4B).  Extent  of  down-regulation  of
ALDH1A1 upon simultaneous exposure to PITX2 siRNA and
H2O2  (−5.1×)  was  comparable  to  effect  of  H2O2  alone
(p=0.566),  suggesting  that  H2O2  and  PITX2  may  affect
ALDH1A1 expression by a common pathway (Figure 4A). It
is known that Wnt signaling increases PITX2 expression in
Figure  1.  PITX2  transcription
knockdown  by  PITX2  siRNA-1  and
PITX2 siRNA-2 as assessed by real time
PCR.
TABLE 2. EFFECT OF PITX2 SIRNAS ON HOUSEKEEPING GENES ACTB, Β2M, AND GAPDH BASED ON MICROARRAY DATA.
Gene TM1* TM2* Average**
ACTB 0.85 0.86 0.85
B2M 1.13 1.23 1.18
GAPDH 0.98 0.98 0.98
                    *Average effect of 2 siRNAs on each TM. **Average effect of 2 siRNAs on TM1 and TM2.
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)various organs including the eye [45]. Lithium mimics the
Wnt  pathway  by  suppressing  GSK-3  activity  and  LiCl  is
commonly used in experimental settings to produce this effect
[38]. Human TM cells possess a functional Wnt signaling
pathway and Wnt signaling is implicated in glaucoma [46].
Here,  it  was  observed  that  LiCl  indeed  enhanced  PITX2
expression (+2.2×). Furthermore, it seemed to moderately
affect increased expression of ALDH1A1 as well, both at RNA
(+1.6×;  Figure  4A)  and  protein  (Figure  4B)  levels.
Pretreatment with LiCl partly prevented H2O2 induced down-
regulation of both PITX2 (−2.3× versus −3.2×; p=0.226) and
ALDH1A1  (−1.6×  versus  −3.9×;  p=0.076;  Figure  4A).
Although  the  differences  did  not  achieve  statistical
significance,  these  preliminary  results  are  suggestive  and
deserve to be pursued. The observations are consistent with
the proposal that ALDH1A1 may at least partly be affected by
the Wnt signaling pathway and that effects on ALDH1A1
expression may be via PITX2.
DISCUSSION
Analysis  of  microarray  gene  expression  data  can  be
confounded  by  compound  effects  of  technical  parameters
causing false positive and false negative identifications and
by low but biologically significant differences in expression
levels of some genes [47]. With these considerations in mind,
we analyzed the array data using three different protocols, the
commonly used protocol available in the Limma package and
two additional ones that we designed [15]. The likelihood of
a  selected  gene  being  a  true  positive  was  considered  to
correlate  with  the  number  of  protocols  by  which  it  was
selected. By considering all genes that were selected by at least
one protocol, the likelihood of false negatives was expected
to  decrease.  The  Limma  protocol  is  based  on  statistical
parameters [15]. Protocols 2 and 3 are both based on fold
change in expression levels, with the consideration that genes
that show larger fold change are likely to be true positives
[47]. Furthermore, data emanating from protocol 1 do not
distinguish between comparisons between treated sample and
each of two controls separately [15]. Although results on our
control repeats showed good reproducibility (only one gene
with difference in fold expression >2), even small differences
in  controls  will  affect  identification  of  genes  affected  by
siRNA  treatments  at  low  (e.g.,  2  fold)      but       possibly
biologically significant levels. Protocol 2 produces separate
Figure 2. Real time PCR confirmation of selected genes affected by PITX2 siRNAs. All genes tested were among PITX2-filtered genes except
DKK1 and KCNJ2. For each TM, the four pair of bars show log2 fold change in expression based on data of each of two PITX2 siRNAs
compared to each of two controls exposed to scrambled siRNA. Standard deviations for real time PCR data are shown. See text for further
details on real time PCR experiments.
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1215data  that  reflect  effect  of  PITX2  siRNA  treatments  as
compared to each of controls. Protocol 3 aims to take into
account variations in results between the two different PITX2
siRNAs  and  the  two  different  TMs.  This  protocol  makes
comparisons between PITX2 siRNA treated cells and average
of controls. Although protocols 2 and 3 both consider fold
change  in  expression,  they  are  different  as  evidenced  by
incomplete overlap between selected genes. Only 8 of 15
genes selected by protocol 2 are among the 20 genes selected
by protocol 3. The Limma protocol selected a larger number
of genes than either protocol 2 or 3. We feel most confident
that  the  5  genes  whose  expressions  were  assessed  to  be
affected by PITX2 knockdown using all three protocols are
true positives. Consistent with expectations of our analysis
protocol, three of the (DIRASS3, CXCL6, and SAMD5) five
common genes are among the five genes that showed highest
fold  change  in  all  three  protocols  (Table  3).  Genes  that
exhibited a lower fold change as result of PITX2 knockdown
were more likely to be selected by only one or two of the
protocols. It is expected that at least some genes identified by
only one or two of the protocols will prove to be biologically
significant.  ADAMTS5  only  identified  by  protocol  2  and
Figure 3. Confirmation of effects of PITX2 knockdown on ALDH1A1 and CXCL6 at the protein level. Results shown are with PITX2 siRNA-1
and TM1. A: Representative western immunoblots of ALDH1A1 and CXCL6 in protein extracts of TM cultures exposed to scrambled siRNA
and PITX2 siRNA. B-G: Immunofluorescent analysis of ALDH1A1expression in TM cultured cells exposed to scrambled siRNA (B, C) and
PITX2 siRNA (D, E). In cells treated with scrambled siRNA (B), ALDH1A1 expression is apparent in cytoplasm and nucleus of most cells.
However, decreased expression is evident in many PITX2 siRNA treated cells (D). No immunofluorescence is observed in the negative control
(F). DAPI stained cells are also shown (C, E, G). H-S: Immunohistochemical demonstration of ALDH1A1 and CXCL6 expression in the
human eye. Cryosections of anterior section of donated globe observed under light microscope (H, K), by immunofluoresence after staining
for ALDH1A1 and CXCL6 (I, L, N, O), and after staining with DAPI (J, M, Q, R) are shown. H, I, J: sections stained with anti-ALDH1A1.
K, L, M: sections stained with anti-CXCL6. Expression of both ALDH1A1 and CXCL6 in the trabecular meshwork (TM) and stroma (S),
and higher expression in the Descemet membrane (DM) are evident. N, Q: highest expression of ALDH1A1 was observed in the epithelium
of the cornea (EP). O, R: highest expression of CXCL6 was observed in the iris (I), particularly in the iris epithelium. P, S: negative control
shows no immunofluorescent staining. Optical lens magnification 5× (all except O and R), 20× (O and R).
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1216NOMO2 identified only by protocol 3 may be good candidate
genes  [17,21,22,48].  CFL2  which  showed  3.2  fold
upregulation  was  not  selected  by  protocol  1.  Results  of
microarray  data  analysis  on  several  genes,  including
assessment of absence of effect of knockdown on ACTB,
β2M, and GAPDH by all of the protocols, were confirmed by
real time PCR analysis. However, DKK1 and KCNJ2 not
selected  by  any  of  the  three  protocols  were  shown  to  be
affected  as  assessed  by  real  time  PCR  (Figure  2).  This
observation is consistent with the notion that there were false
negatives. Our experiments do not allow definitive assessment
of false positives; however, it was reassuring that results on
several TM1 and TM2 microarray based selected genes were
confirmed by real time PCR in the two independent TM4 and
TM5 cultures (Figure 2). Furthermore, the results on TM4 and
TM5 suggest that at least some observed PITX2 effects persist
from  the  second  to  sixth  decade  of  life.  Finally,  the
observation that a notable number of genes identified here
were  previously  implicated  in  studies  that  have  biologic
relevance to this study is unlikely to be coincidental (Table 5).
Our findings for the first time suggest that PITX2 affect the
expression of some of these genes.
TABLE 4. PITX2 AFFECTED GENES IDENTIFIED IN OTHER GLAUCOMA RELATED GLOBAL GENE EXPRESSION STUDIES*.
PITX2 filtered genes Number of other studies in which affected gene identified Reference
CXCL6 3 [18-20]
ADAMTS5 3 [17,21,22]
DIRAS3 2 [17,19]
BBS5 1 [17]
ELK3 1 [29]
GRP 1 [21]
HAPLN1 1 [18]
MICALL2 1 [17]
PLP2 1 [30]
SLC12A2 1 [18]
ALDH1A1 1 [27]
DKK1** 1 [22]
KCNJ2** 1 [16]
        *PITX2 filtered genes reported here were sought in lists of selected genes of the array studies reported in references [16-30].
        **These 2 included were based on real time PCR results.
Figure 4. Effects of H2O2 and LiCl on
ALDH1A1 expression in TM1 cells. A:
As assessed by real time PCR. See text
for details of treatments. Results shown
are  average  of  three  independent
experiments.  Two  duplicate  real  time
PCRs  were  performed  in  each
experiment.  Standard  deviations  are
shown. β2M was used as control gene.
B: As assessed by western blotting.
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1217Two  sets  of  PITX2  related  terms  identified  by  the
bioinformatics  approach  are  notable,  phagocytosis  and
immune system related functions. Phagocytosis is recognized
as an important function of human TM cells, partly because it
results in clearing of substances that may hinder facile outflow
of aqueous humor [49]. Immune related functions constitute
eight of the 29 terms for enriched PITX2 related functions
listed in Table 4, and clinical and experimental studies suggest
that immune system functions are involved in glaucoma [50].
Furthermore, immune related functions may be relevant to
phagocytosis  in  the  TM  [51].  Two  genes,  CXCL6  and
ALDH1A1, were prioritized further analysis.
CXCL6 codes a pro-inflammatory cytokine that induces
directed migration of monocytes and neutrophils [52]. It has
been identified to be modulated in three previous glaucoma
related global gene analyses [18-20]. Most recently, it was
reported that human TM cells secrete significant quantities of
CXCL6 [10]. The authors implicated cytokines in regulation
of aqueous humor outflow, a function clearly relevant to the
glaucoma  phenotype  [53,54].  Here  for  the  first  time  we
present evidence that PITX2 directly or indirectly affects the
expression of this gene. The earlier observations, our finding
that  CXCL6  expression  is  affected  by  PITX2,  and  that
PITX2 mutations can cause glaucoma associated ARS suggest
that PITX2 may affect the ARS and glaucoma phenotypes via
an effect on the immune response mediated by CXCL6.
Down-regulation of ALDH1A1 and its expression in the
human  eye,  most  highly  in  the  corneal  epithelium,  were
demonstrated (Figure 3). ALDH1A1 and ALDH3A1, also
expressed in the anterior segment of mammalian eyes, are
aldehyde  dehydrogenases  that  minimize  the  deleterious
effects  of  oxidative  damage  caused  largely  by  ultraviolet
radiation [55]. Highly reactive electrophilic products of lipid
peroxidation,  4-hydroxy-2-nonenal  (4-HNE)  and  malon-
dialdehyde  (MDA),  are  among  the  agents  that  promote
oxidative damage [56]. Whereas ALDH1A1 metabolizes both
4-HNE and MDA, MDA is a poor substrate for the more
abundant  ALDH3A1  [57].  Notably,  mouse  knockouts  of
ALDH1A1 exhibited lens opacity later than ALDH3A1 and
ALDH1A1  double  knockouts  [11].  Similarly,  some
phenotypic consequences in ALDH1A1 knockouts became
evident only at an embryonic stage when ALDH3A1was no
longer expressed [58]. Late onset glaucoma in some ARS
patients harboring PITX2 mutations may be due to existence
of proteins that complement ALDH1A1 activity.
Oxidative  stress  is  an  important  component  in  the
etiology of glaucoma [59]. Moreover, existence of oxidative
stress protection mechanisms and physiologic consequences
of oxidative stress in the human TM cells have been reported
TABLE 5. FUNCTIONAL ANNOTATIONS ENRICHED FOR GENES AFFECTED BY PITX2 SIRNAS*.
Category GO ID and Term Number of genes p value
GOTERM_CC_ALL GO:0016363~nuclear matrix 2 0.0013123
GOTERM_BP_ALL GO:0030098~lymphocyte differentiation 4 0.0013564
GOTERM_CC_ALL GO:0034399~nuclear periphery 2 0.001421
GOTERM_CC_ALL GO:0005789~endoplasmic reticulum membrane 3 0.0014526
KEGG_PATHWAY hsa04666:Fc gamma R-mediated phagocytosis 2 0.0020273
GOTERM_BP_ALL GO:0002520~immune system development 5 0.0026937
GOTERM_BP_ALL GO:0002521~leukocyte differentiation 4 0.0026975
GOTERM_MF_ALL GO:0019901~protein kinas binding 3 0.005062
GOTERM_MF_ALL GO:0030246~carbohydrate binding 4 0.0055687
GOTERM_MF_ALL GO:0019900~kinase binding 3 0.0071612
GOTERM_BP_ALL GO:0046649~lymphocyte activation 4 0.0086461
GOTERM_BP_ALL GO:0030097~hemopoiesis 4 0.0137107
GOTERM_BP_ALL GO:0006955~immune response 6 0.0145876
GOTERM_BP_ALL GO:0045321~leukocyte activation 4 0.0146618
GOTERM_CC_ALL GO:0042175~nuclear envelope-endoplasmic reticulum network 3 0.0158339
GOTERM_CC_ALL GO:0070160~occluding junction 2 0.0167652
GOTERM_CC_ALL GO:0005923~tight junction 2 0.0167652
GOTERM_BP_ALL GO:0048534~hemopoietic or lymphoid organ development 4 0.0177369
GOTERM_CC_ALL GO:0043232~intracellularnon-membrane-bounded organelle 10 0.0186364
GOTERM_CC_ALL GO:0043228~non-membrane-bounded organelle 10 0.0186364
GOTERM_CC_ALL GO:0009898~internal side of plasma membrane 3 0.0186943
GOTERM_CC_ALL GO:0044432~endoplasmic reticulum part 3 0.0215332
GOTERM_CC_ALL GO:0005783~endoplasmic reticulum 5 0.0216708
GOTERM_CC_ALL GO:0043296~apical junction complex 2 0.0220511
GOTERM_CC_ALL GO:0016327~apico lateral plasma membrane 2 0.0226397
GOTERM_BP_ALL GO:0001775~cell activation 4 0.0229807
GOTERM_CC_ALL GO:0005730~nucleolus 4 0.0253255
GOTERM_CC_ALL GO:0070013~intracellular organelle lumen 7 0.0281463
GOTERM_BP_ALL GO:0010557~positive regulation of macromolecule biosynthetic process 5 0.0492617
                 *Enriched among 41 PITX2 genes identified by ≥1 array data analysis protocols.
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1218[60,61].  Treatment  of  TM  cells  with  a  relatively  high
concentration  of  H2O2  caused  decreased  expression  of
PITX2  and  ALDH1A1,  suggesting  that  ALDH1A1  is  a
component of the oxidative response in TM cells and that
oxidative stress effects on ALDH1A1 may be mediated by
PITX2 (Figure 4). Although the data are preliminary, they are
consistent with the proposal that down-regulation of PITX2
causes  decreased  ALDH1A1  expression,  and  this  may
contribute to evolvement of the ARS phenotype, including its
glaucoma  related  features,  via  oxidative  stress  related
pathways.
Some of the other genes affected by PITX2 are relevant
to maintenance of homeostasis in TM cells. Expression of
DIRAS3 which is a Rho GTPase exhibited maximum down-
regulation  by  PITX2  knockdown  (Table  3).  It  has  been
reported  that  ectopically  expressed  PITX2  in  HeLa  cells
profoundly affected the cells’ morphology, migration, and
proliferation, and that these effects were mediated through
Rho GTPase signaling [62]. Furthermore, myocilin induced
loss of actin stress fibers, focal adhesion, and cell matrix
cohesiveness  in  the  TM  was  mediated  by  Rho  GTPase
inhibition [63]. MEIS2, regulated by Pax6 and miRNA-204,
has roles in vertebrate eye development [64,65]. We show
here  that  MEIS2  expression  is  also  affected  by  PITX2,
suggesting  a  complicated  interaction  between  PITX2  and
PAX6 in directing ocular development. PITX2 and MEIS2
were shown to have identical spatial and temporal expression
patterns in chicken embryonic facial prominences; cranio-
facial anomalies are among the manifestations observed in
ARS patients [66].
In  conclusion,  the  results  presented  suggest  that  the
analysis of the microarray data has led to identification of
genes whose expressions are truly affected by PITX2. We
expect  that  the  approach  used  allowed  identification  of
important  functions  not  easily  identified  by  genetic
approaches because of their subtle effects and because of
existence of compensatory mechanisms. The same approach
can be applied for FOXC1, which is also mutated in some ARS
patients [9]. Addressing the functions and expression patterns
of  identified  genes  may  lead  to  better  understanding  of
biochemical and physiologic pathways leading to glaucoma.
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